Taxotere, Eloxatin Flat Sales Show Challenges Of Crowding Oncology Market
Nearly flat sales growth in the U.S. for Sanofi-Aventis' Eloxatin and Taxotere may be indicative of challenges facing manufacturers as more and more oncologics enter the market
You may also be interested in...
Increasing competition could negatively impact market potential for biotech products, Merrill Lynch's David Munno suggested
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials